Education
About Us
Working with TipRanks
Follow Us
Virax Biolabs Group Ltd. Class A (VRAX)
NASDAQ:VRAX
Total Valuation
Virax Biolabs Group Ltd. Class A has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Virax Biolabs Group Ltd. Class A has 4,341,956 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,341,956
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Virax Biolabs Group Ltd. Class A’s return on equity (ROE) is -1.25 and return on invested capital (ROIC) is -121.13%.
Return on Equity (ROE)-1.25
Return on Assets (ROA)-1.23
Return on Invested Capital (ROIC)-121.13%
Return on Capital Employed (ROCE)-1.22
Revenue Per Employee9.20K
Profits Per Employee-396.42K
Employee Count17
Asset Turnover0.03
Inventory Turnover1.75
Valuation Ratios
The current PE Ratio of Virax Biolabs Group Ltd. Class A is -0.22. Virax Biolabs Group Ltd. Class A’s PEG ratio is -0.02.
PE Ratio-0.22
PS Ratio0.00
PB Ratio0.36
Price to Fair Value0.27
Price to FCF-0.81
Price to Operating Cash Flow-0.67
PEG Ratio-0.02
Income Statement
In the last 12 months, Virax Biolabs Group Ltd. Class A had revenue of 156.42K and earned -6.73M in profits. Earnings per share was -3.36.
Revenue156.42K
Gross Profit50.59K
Operating Income-6.50M
Pretax Income-6.74M
Net Income-6.73M
EBITDA-6.61M
Earnings Per Share (EPS)-3.36
Cash Flow
In the last 12 months, operating cash flow was -4.71M and capital expenditures -707.92K, giving a free cash flow of -5.42M billion.
Operating Cash Flow-4.71M
Free Cash Flow-5.42M
Free Cash Flow per Share-1.25
Dividends & Yields
Virax Biolabs Group Ltd. Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.51
52-Week Price Change28.57%
50-Day Moving Average1.12
200-Day Moving Average1.92
Relative Strength Index (RSI)49.16
Average Volume (3m)222.99K
Important Dates
Virax Biolabs Group Ltd. Class A upcoming earnings date is Feb 2, 2023, TBA Not Confirmed.
Last Earnings DateInvalid Date
Next Earnings DateFeb 2, 2023
Ex-Dividend Date―
Financial Position
Virax Biolabs Group Ltd. Class A as a current ratio of 25.94, with Debt / Equity ratio of 6.98%
Current Ratio25.94
Quick Ratio25.58
Debt to Market Cap0.00
Net Debt to EBITDA0.51
Interest Coverage Ratio-241.70
Taxes
In the past 12 months, Virax Biolabs Group Ltd. Class A has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Virax Biolabs Group Ltd. Class A EV to EBITDA ratio is 0.29, with an EV/FCF ratio of 0.26.
EV to Sales-12.08
EV to EBITDA0.29
EV to Free Cash Flow0.26
EV to Operating Cash Flow0.30
Balance Sheet
Virax Biolabs Group Ltd. Class A has $7.38M in cash and marketable securities with $603.20K in debt, giving a net cash position of -$6.78M billion.
Cash & Marketable Securities$7.38M
Total Debt$603.20K
Net Cash-$6.78M
Net Cash Per Share-$1.56
Tangible Book Value Per Share$2.54
Margins
Gross margin is 39.59%, with operating margin of -4153.25%, and net profit margin of -4304.81%.
Gross Margin39.59%
Operating Margin-4153.25%
Pretax Margin-4308.38%
Net Profit Margin-4304.81%
EBITDA Margin-4225.28%
EBIT Margin-4291.19%
Analyst Forecast
The average price target for Virax Biolabs Group Ltd. Class A is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$3.00
Price Target Upside183.02% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―